Zenosense, Inc. (ZENO) Gaining Steam as Lung Cance
Post# of 53
Posted On: 03/23/2015 6:11:43 PM
Zenosense, Inc. (ZENO) Gaining Steam as Lung Cancer Detection Trial Ramps Up
Zenosense has been working with a large university hospital in Madrid, Spain to test the effectiveness of its specially designed volatile organic compound (VOC) detection techniques. The collaboration is particularly promising, because, in addition to its work with Zenosense, the university hospital has been directly involved in a number of published studies focusing on the detection of VOCs in order to better identify various respiratory pathologies.
While the 400 subject trial will serve as an excellent proof of concept, Zenosense hopes to considerably increase the size of its tests following positive initial results. The company expects the initial trial to take nine months and involve four distinct groups of subjects including healthy smokers, non-smokers and those with diagnosed lung cancer and Chronic Obstructive Pulmonary Disease. The company has already been approved by the ethics committee of the university hospital, meaning that broadening participation to include a host of other public hospitals throughout Spain is possible without the need for further approvals.
If the trials prove successful, Zenosense will be one step closer to taking its revolutionary diagnostic systems to the market. By allowing for superior early detection of lung cancer through non-invasive means, there’s little doubt that the company’s devices would be in a great position to experience tremendous demand. The company predicts that having a way to improve early detection through cost effective screening techniques could offer noticeable improvements to the survivability rates of lung cancer and similar ailments.
VOC detection is a tried and tested method of diagnosing diseases. Just as highly trained dogs have been able to recognize prostate cancer-specific VOCs with up to 98 percent accuracy, Zenosense’s use of a common Electronic Nose technology platform puts it in a great position to improve diagnostic accuracy for a wide range of diseases.
As the company’s trial continues to ramp up, look for Zenosense to make some major waves in the medical and diagnostic industries in the near future. With the possibility of dramatically improving the survivability of some of the world’s most deadly illnesses and servicing multi-billion dollar industries, the sky could be the limit for this detection device development company.
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Zenosense has been working with a large university hospital in Madrid, Spain to test the effectiveness of its specially designed volatile organic compound (VOC) detection techniques. The collaboration is particularly promising, because, in addition to its work with Zenosense, the university hospital has been directly involved in a number of published studies focusing on the detection of VOCs in order to better identify various respiratory pathologies.
While the 400 subject trial will serve as an excellent proof of concept, Zenosense hopes to considerably increase the size of its tests following positive initial results. The company expects the initial trial to take nine months and involve four distinct groups of subjects including healthy smokers, non-smokers and those with diagnosed lung cancer and Chronic Obstructive Pulmonary Disease. The company has already been approved by the ethics committee of the university hospital, meaning that broadening participation to include a host of other public hospitals throughout Spain is possible without the need for further approvals.
If the trials prove successful, Zenosense will be one step closer to taking its revolutionary diagnostic systems to the market. By allowing for superior early detection of lung cancer through non-invasive means, there’s little doubt that the company’s devices would be in a great position to experience tremendous demand. The company predicts that having a way to improve early detection through cost effective screening techniques could offer noticeable improvements to the survivability rates of lung cancer and similar ailments.
VOC detection is a tried and tested method of diagnosing diseases. Just as highly trained dogs have been able to recognize prostate cancer-specific VOCs with up to 98 percent accuracy, Zenosense’s use of a common Electronic Nose technology platform puts it in a great position to improve diagnostic accuracy for a wide range of diseases.
As the company’s trial continues to ramp up, look for Zenosense to make some major waves in the medical and diagnostic industries in the near future. With the possibility of dramatically improving the survivability of some of the world’s most deadly illnesses and servicing multi-billion dollar industries, the sky could be the limit for this detection device development company.
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)Zenosense Inc. (ZENO) Stock Research Links
Scroll down for more posts ▼